Effect of Eleven Flavored Shenqi Tablets Combined with Human Granulocyte Stimulating Factor in the Treatment of Breast Cancer Patients with Chemotherapy and Its Influence on Bone Marrow Suppression
Objective:To study the effect of Eleven Flavored Shenqi Tablets combined with Human Granulocyte Stimulating Factor in the treatment of breast cancer patients with chemotherapy and its influence on bone marrow suppression.Method:A total of 82 breast cancer chemotherapy patients admitted to Qidong Traditional Chinese Medicine Hospital from January 2020 to January 2023 were selected.They were divided into study group and control group according to random number table method,with 41 cases in each group.The control group was given Human Granulocyte Stimulating Factor Injection treatment,and the study group was given Eleven Flavored Shenqi Tablets combined with Human Granulocyte Stimulating Factor treatment.The incidence of myelosuppression,blood routine indexes,immune function before and after 1 week of treatment and adverse reactions were compared between the two groups.Result:The incidence of myelosuppression in the study group was lower than that in the control group,the difference was statistically significant(P＜0.05).After 1 week of treatment,white blood cell counts(WBC),hemoglobin(Hb),platelet counts(PLT)and neutrophil count(NEUT)were decreased in both groups,WBC,Hb,PLT and NEUT in the study group were higher than those in the control group,and the differences were statistically significant(P＜0.05).After 1 week of treatment,CD3+,CD4+ and CD8+ were decreased in both groups,and CD3+,CD4+ and CD8+ in the study group were higher than those in the control group,the differences were statistically significant(P＜0.05).The scores of bone pain,fever,fatigue,headache and dizziness in the study group were lower than those in the control group,the differences were statistically significant(P＜0.05).Conclusion:When breast cancer patients undergo chemotherapy,the combination of Eleven Flavored Shenqi Tablets combined with Human Granulocyte Stimulating Factor treatment can effectively reduce the risk of bone marrow suppression,maintain the blood routine level and immune function,effectively reduce the incidence of adverse reactions of patients.
国家科技期刊平台
NSTL
万方数据
